

Surrey and Sussex Healthcare NHS Trust (SASH) have started to change from Clexane® (enoxaparin) to Inhixa®, the biosimilar enoxaparin, for all new low-molecular weight heparin initiations. **All prescribing must be by brand.**

[MHRA advice](#) is that a biological medicine (including biosimilars) should be prescribed by brand name as this supports pharmacovigilance and continuity of supply for the patient.

[https://www.abpi.org.uk/media/1391/biological\\_biosimilar\\_medicine\\_uk.pdf](https://www.abpi.org.uk/media/1391/biological_biosimilar_medicine_uk.pdf)

**East Surrey (CRESH) in conjunction with SASH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.**

**Clexane®** pre-filled syringes are presented either with or without an automatic needle safety guard which is activated when the full dose has been administered.

**Inhixa®** pre-filled syringes have a needle safety guard that activates when the needle is withdrawn after administration of the full dose and the plunger is pressed in further.

**Please note:**

[Inhixa®](#) has different colour coding to the originator Clexane®.



It is therefore important that the patient receives the same brand that they have been initiated on and been given appropriate training by the health care professional.

Please click on the link for a video demonstrating the administration of Inhixa®:

<http://www.techdow-pharma.co.uk/productsInfo/>

Further resources (including patient instruction leaflets, recommended) and training to support the use of Inhixa® can be obtained from:

Angela Willcocks [angela.willcocks@uk.techdow.com](mailto:angela.willcocks@uk.techdow.com) 07949 812432

**Prescribing data shows that some patients have been receiving generic prescriptions for enoxaparin.**

**Please check that all patient are now prescribed enoxaparin by brand only for safety and continuity of care.**